Senate Lawmakers Unveil Coronavirus Relief Measure

On July 27, 2020, Republican lawmakers in the Senate unveiled a $1 trillion stimulus package to address the impacts of the ongoing coronavirus pandemic. The Health, Economic Assistance, Liability, and Schools Act or HEALS Act includes $105 billion in education funding; a “liability shield” to protect businesses, universities, schools, and hospitals from coronavirus-related lawsuits; another round of direct stimulus payments to American households; additional funding for the Paycheck Protection Program and emergency business loans; and a two-thirds reduction in emergency federal supplemental unemployment payments. The bill does not include any aid for state and local governments, but it allows for more flexibility in how states allocate funds. Of the $105 billion proposed for education funding, $70 billion would be targeted to K-12 schools. Two-thirds of that funding is intended to help schools reopen for in-person teaching. Schools would need to meet certain “minimum opening requirements” established by their states to receive those funds. President Trump previously threatened to withdraw federal funding from schools that don’t reopen. Additionally, $29 billion would be directed to higher education institutions and $5 billion to governors to allocate to either higher education or K-12 schools. The Heroes Act - the $3 trillion relief package passed by the U.S. House of Representatives in May - included $8.4 billion for higher education instituti...
Source: Public Policy Reports - Category: Biology Authors: Source Type: news

Related Links:

o-Wei Wei The transmission and evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are of paramount importance in controlling and combating the coronavirus disease 2019 (COVID-19) pandemic. Currently, over 15,000 SARS-CoV-2 single mutations have been recorded, which have a great impact on the development of diagnostics, vaccines, antibody therapies, and drugs. However, little is known about SARS-CoV-2’s evolutionary characteristics and general trend. In this work, we present a comprehensive genotyping analysis of existing SARS-CoV-2 mutations. We reveal that host immune response via APOB...
Source: Viruses - Category: Virology Authors: Tags: Article Source Type: research
Jenny Mikakos quits in wake of inquiry into hotel quarantine;Madrid braces for lockdown as Spain reaches 716,481 total infections;surge in cases in AthensFigures prompt French and Dutch warnings, and row in SpainUS approaches 7m cases as officials warn surge could comeWhat lessons can Europe learn from Sweden ’s experience?Why dogs might be a Covid tester ’s best friend1.37amBSTThis blog is closing now but thanks for reading. You can keep following developments in the pandemic at our new live blog with Melissa Davey here:Related:Coronavirus live news: WHO warns 2m could die before vaccine; Victoria's health min...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Coronavirus outbreak World news UK news US news Australia news Science Infectious diseases Source Type: news
The PM will call on world leaders to set aside differences as he sets out plans to prevent future pandemics.
Source: BBC News | Health | UK Edition - Category: Consumer Health News Source Type: news
Interim analysis from the ongoing Phase 1/2a clinical trial of the Janssen COVID-19 vaccine candidate (JNJ-78436735) was posted today on the pre-print server medRxiv.The data demonstrate that a single dose of JNJ-78436735 induced a strong neutralizing antibody response in nearly all participants aged 18 years and older and was generally well-tolerated. Immune responses were similar across the age groups studied, including older adults. The ongoing Phase 1/2a clinical trial is designed to study the safety and immunogenicity of two dose levels of the Janssen COVID-19 vaccine, and as single and two-dose schedules. The interim...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
Authors: Mishra VN, Kumari N, Pathak A, Chaturvedi RK, Gupta AK, Chaurasia RN Abstract An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan City, China, in December 2019. Since then, the outbreak has grown into a global pandemic, and neither a vaccine nor a treatment for the disease, termed coronavirus disease 2019 (COVID-19), is currently available. The slow translational progress in the field of research suggests that a large number of studies are urgently required. In this context, this review explores the impact of bacteriophages on SARS-CoV-2, especially conce...
Source: International Journal of Microbiology - Category: Microbiology Tags: Int J Microbiol Source Type: research
David Brenner joins TWiV to explain how far-UVC lights could provide protection from SARS-CoV-2 and other airborne viruses in public places, solutions to face mask fogging, transmission during airplane flights, and listener questions. Click arrow to playDownload TWiV 666 (78 MB .mp3, 129 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Show notes at microbe.tv/twiv
Source: virology blog - Category: Virology Authors: Tags: This Week in Virology airborne inactivation airplane transmission coronavirus COVID-19 face mask far-UVC fogging pandemic SARS-CoV-2 UV light vaccine viral viruses Source Type: blogs
Michael T. Osterholm, PhD, MPH, returns to JAMA's Coronavirus Q&A series to discuss the latest developments in the COVID-19 pandemic. He is director of the Center for Infectious Disease Research and Policy (CIDRAP) at University of Minnesota and a veteran of pandemic planning. Recorded September 23, 2020. Related Article(s): Fairly Prioritizing Groups for Access to COVID-19 Vaccines
Source: JAMA Author Interviews - Category: General Medicine Authors: Source Type: podcasts
Authors: Madubueze CE, Dachollom S, Onwubuya IO Abstract Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS CoV-2). It was declared on March 11, 2020, by the World Health Organization as pandemic disease. The disease has neither approved medicine nor vaccine and has made governments and scholars search for drastic measures in combating the pandemic. Regrettably, the spread of the virus and mortality due to COVID-19 has continued to increase daily. Hence, it is imperative to control the spread of the disease particularly using nonpharmacological strategie...
Source: Computational and Mathematical Methods in Medicine - Category: Statistics Tags: Comput Math Methods Med Source Type: research
Authors: Chukwudozie OS, Chukwuanukwu RC, Iroanya OO, Eze DM, Duru VC, Dele-Alimi TO, Kehinde BD, Bankole TT, Obi PC, Okinedo EU Abstract The novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has previously never been identified with humans, thereby creating devastation in public health. The need for an effective vaccine to curb this pandemic cannot be overemphasized. In view of this, we designed a subcomponent antigenic peptide vaccine targeting the N-terminal (NT) and C-terminal (CT) RNA binding domains of the nucleocapsid protein that aid in viral replica...
Source: Journal of Immunology Research - Category: Allergy & Immunology Tags: J Immunol Res Source Type: research
Children have been relatively spared from the effect of clinical coronavirus disease 2019 (COVID-19). The newly described inflammatory syndrome is rare in terms of the total population of children, and severe acute forms of COVID-19 are even rarer in children and young people. Despite this, both experts and the public have struggled to come to terms with the fact that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is also different from all other known respiratory viral infections: there is significant uncertainty regarding children and young people ’s ability to catch, transmit, and spread the virus. W...
Source: JAMA Pediatrics - Category: Pediatrics Source Type: research
More News: American Health | Biology | China Health | Colleges | Coronavirus | COVID-19 | Education | Emergency Medicine | Funding | Government | Grants | Hospitals | Lawsuits | Legislation | National Institutes of Health (NIH) | Pandemics | Schools | Science | Tax | Teaching | Trump | Unemployment | Universities | Universities & Medical Training | USA Health | Vaccines